EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Molecular Characterization and Clinical Relevance of MGMT ‐Silenced Pancreatic Cancer

Federico Nichetti iD, Marco Silvestri iD, Luca Agnelli, Andrea Franza, Chiara Pircher, Simone Rota, Paolo Ambrosini, Giuseppe Fotia, Jennifer Hüllein, Giovanni Randon, Panna Lajer, Federica Perrone und 16 weitere

Cancer Medicine · 2024

DOI: 10.1002/cam4.70393 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, 2024. Verfasst von Federico Nichetti und 27 weiteren Autor:innen. Beteiligte Einrichtung: Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Tumor Suppressor Proteins, DNA Modification Methylases, DNA Repair Enzymes. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The identification of actionable molecular targets of pancreatic cancer (PAC) is key to improving patient outcomes. We hypothesized O6‐methylguanine‐DNA methyltransferase ( MGMT ) silencing may occur in a subset of PAC tumors, with unexplored clinical and molecular correlates. Experimental Design We leveraged sequencing data from The Cancer Genome Atlas (TCGA), the Clinical Proteomic Tumor Analysis Consortium 3 (CPTAC‐3), and the (Australian Pancreatic Cancer Genome Initiative) PACA‐AU cohorts to characterize MGMT ‐silenced PAC. Genomic, transcriptomic, methylation, and clinical data were investigated, and findings were validated in silico using methylation, transcriptomic and drug sensitivity data from Cancer Cell Line Encyclopedia (CCLE) project, and in a real‐world cohort of PAC patients profiled for MGMT status at Istituto Nazionale Tumori of Milan (INT).

Results

On the basis of Human Methylation 450k data, MGMT silencing was identified in ~6% of PAC cases and was enriched in tumors with non‐ductal histology, with a trend toward longer overall survival. MGMT ‐silenced tumors were associated with a lower frequency of KRAS mutations and showed features of immune exclusion. In the INT cohort, MGMT ‐silencing was confirmed in ~7% of cases and prevalent in KRAS wild type tumors, with a favorable prognostic impact. In silico analysis suggested a higher sensitivity to alkylating and DNA damaging agents in MGMT ‐silenced PAC cell lines.

Conclusions

MGMT silencing occurs in a small subgroup of PACs and is enriched in KRAS wild type cases, with a favorable prognostic impact. Our findings provide the rationale to explore combinations of alkylating with DNA damaging agents in MGMT ‐silenced PAC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pancreatic NeoplasmsTumor Suppressor ProteinsDNA Modification MethylasesDNA Repair EnzymesDNA MethylationGene SilencingHumansMaleFemaleAgedMiddle AgedCell Line, TumorGene Expression Regulation, NeoplasticPrognosisBiomarkers, TumorClinical Relevance

Stichwörter der Autor:innen

KRAS wild typeMGMTbiomarkermolecular profilingpancreatic cancertemozolomide

Substanzen

Tumor Suppressor ProteinsDNA Modification MethylasesMGMT protein, humanDNA Repair EnzymesBiomarkers, Tumor

Autor:innen und Institutionen

  • Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy.
  • Computational Oncology, Molecular Precision Oncology Program, National Center for Tumor Diseases (NCT) and German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Department of Diagnostic Innovation, Second Division of Pathology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
  • Division of Translational Medical Oncology, Section of Translational Cancer Epigenomics, German Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT), Heidelberg, Germany.
  • Department of Pathology and Laboratory Medicine, First Division of Pathology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
  • Hepato-Pancreato-Biliary Surgery and Liver Transplantation, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.

ORCID-Profile: Federico Nichetti, Marco Silvestri, Filippo Pietrantonio

Zitieren

APA

Nichetti, F., Silvestri, M., Agnelli, L., Franza, A., Pircher, C., Rota, S., Ambrosini, P., Fotia, G., Hüllein, J., Randon, G., Lajer, P., Perrone, F., Tamborini, E., Leoncini, G., Coppa, J., Busset, M. D. D., Pusceddu, S., Milione, M., Morano, F., …, & Niger, M. (2024). Molecular Characterization and Clinical Relevance of MGMT ‐Silenced Pancreatic Cancer. Cancer Medicine. https://doi.org/10.1002/cam4.70393

Vancouver

Nichetti F, Silvestri M, Agnelli L, Franza A, Pircher C, Rota S, et al. Molecular Characterization and Clinical Relevance of MGMT ‐Silenced Pancreatic Cancer. Cancer Medicine. 2024. doi:10.1002/cam4.70393

BibTeX
@article{Nichetti2024,
  author = {Nichetti, Federico and Silvestri, Marco and Agnelli, Luca and Franza, Andrea and Pircher, Chiara and Rota, Simone and Ambrosini, Paolo and Fotia, Giuseppe and Hüllein, Jennifer and Randon, Giovanni and Lajer, Panna and Perrone, Federica and Tamborini, Elena and Leoncini, Giuseppe and Coppa, Jorgelina and Busset, Michele Droz Dit and Pusceddu, Sara and Milione, Massimo and Morano, Federica and Pietrantonio, Filippo and Pruneri, Giancarlo and Mazzaferro, Vincenzo and Lipka, Daniel B and Köhler, Bruno Christian and Hübschmann, Daniel and Fröhling, Stefan and de Braud, Filippo and Niger, Monica},
  title = {Molecular Characterization and Clinical Relevance of MGMT ‐Silenced Pancreatic Cancer},
  journal = {Cancer Medicine},
  year = {2024},
  doi = {10.1002/cam4.70393}
}
Kostenlos starten →